metricas
covid
Clinics Larotrectinib versus infigratinib for adult patients with both glioma and tyrosi...
Journal Information

Statistics

Follow this link to access the full text of the article

Original articles
Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis
Yufang Chena,1, Jian Mab,1, Qianqian Gaoa, Yu Gaia, Yichi Suna, Meihua Wanga,
Corresponding author
wangmeihua1234@suda.edu.cn

Corresponding author.
a Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China
b Department of Oncology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China
Read
1158
Times
was read the article
355
Total PDF
803
Total HTML
Share statistics
Article information
ISSN: 18075932
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 23 14 37
2025 11 49 43 92
2025 10 35 22 57
2025 9 39 20 59
2025 8 32 13 45
2025 7 44 7 51
2025 6 23 0 23
2025 5 38 5 43
2025 4 18 3 21
2025 3 23 4 27
2025 2 17 4 21
2025 1 29 3 32
2024 12 21 2 23
2024 11 48 18 66
2024 10 47 22 69
2024 9 45 22 67
2024 8 41 17 58
2024 7 39 25 64
2024 6 23 6 29
2024 5 35 17 52
2024 4 39 21 60
2024 3 45 19 64
2024 2 50 48 98
Show all

Follow this link to access the full text of the article